SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Virgin Galactic Holdings, Inc. is an aerospace and space travel company, which engages in the provision of consumer space experience using reusable spaceflight systems. The firm is also involved in designing, developing, and manufacturing, ground and flight testing, spaceflight operation, and post-flight maintenance of spaceflight systems. The company was founded on May 5, 2017 and is headquartered in Tustin, CA.

Virgin Galactic Holdings Inc - Ordinary Shares - Class A

Virgin Galactic Holdings Inc

Virgin Galactic is experiencing intense retail momentum driven by speculation that it may act as a proxy play for the highly anticipated SpaceX IPO. The community is actively debating the stock's potential for a massive short squeeze, with many users highlighting the high short interest and low float while skeptics warn of its history of dilution and weak fundamentals.

SoFi Technologies, Inc. is a financial service platform, which engages in the provision of student loan refinancing options to the private student loan market. It operates through the following segments: Lending, Technology Platform, and Financial Services. The Lending segment offers personal loans, student loans, home loan products, and related servicing activities. The Technology Platform segment focuses on technology products and solutions revenue. The Financial Services segment includes the SoFi Money product, SoFi Invest product, SoFi Credit Card product, SoFi Relay personal finance management product, and other financial services. The company was founded in April 2011 and is headquartered in San Francisco, CA.

SoFi Technologies Inc

SoFi Technologies is trending due to the launch of its own stablecoin and building speculation regarding a potential S&P 500 inclusion, which has fueled significant retail interest and short-squeeze chatter. While the stock's high volatility and periodic pullbacks remain a key talking point for the community, many investors are actively discussing the firm's transition into a comprehensive financial super app as a long-term growth catalyst.

Arm Holdings Plc engages in the licensing, marketing, research, and development of microprocessors, systems IP, graphics processing units, physical IP and associated systems IP, software, and tools. It operates through the following geographical segments: United Kingdom, United States, and Other Countries. The company was founded on November 12, 1990 and is headquartered in Cambridge, the United Kingdom.

Arm Holdings plc. - ADR

Arm Holdings Plc.

Arm Holdings is currently experiencing high volatility driven by AI-driven chip architecture hype and aggressive analyst price target revisions, fueling debate over whether the stock is undergoing a legitimate structural re-rating or a speculative bubble. The community is sharply divided, with bulls pointing to the expanding AI infrastructure cycle and long-term licensing growth, while bears emphasize extreme valuation concerns and potential market manipulation.

International Business Machines Corp. is an information technology company, which engages in the provision of integrated solutions that leverage information technology and knowledge of business processes. It operates through the following segments: Software, Consulting, Infrastructure, Financing, and Other. The Software segment combines hybrid cloud platform and software solutions to help clients become more data-driven, and to automate, secure, and modernize their environments. The Consulting segment focuses on integrating skills on strategy, experience, technology and operations by domain and industry. The Infrastructure segment offers solutions for hybrid cloud and is the foundation of the hybrid cloud stack. Infrastructure is optimized for infusing AI into mission-critical transactions and tightly integrated with IBM Software including Red Hat for accelerated hybrid cloud benefits. The Financing segment refers to the client and commercial financing, facilitating IBM clients’ acquisition of IT systems, software, and services. The company was founded by Charles Ranlett Flint and Thomas J. Watson Sr. on June 16, 1911 and is headquartered in Armonk, NY.

International Business Machines Corp.

IBM is seeing increased market attention following government backing for its quantum computing and infrastructure initiatives, leading to heavy discussion around its potential to lead the quantum sector. The community is actively debating whether these strategic catalysts justify the stock's recent volatility and upward price momentum or if it is part of a broader trend of speculative rotation into quantum and AI-related tech.

Keel Infrastructure Corp. engages in building artificial intelligence focused data centers and energy assets. It focuses on infrastructure and energy required to support high-performance computing and artificial intelligence workloads. The company was founded on April 1, 2026 and is headquartered in New York, NY.

Keel Infrastructure Corp.

Keel Infrastructure Corp

Keel Infrastructure is surging as investors speculate on a major AI-driven transformation, fueled by the company's significant power pipeline and expectations of upcoming hyperscale data center lease announcements. The community remains highly bullish, frequently comparing the current setup to previous breakout stocks in the sector and actively monitoring institutional accumulation.

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is experiencing a surge in retail interest driven by strong technical breakouts, heavy volume, and speculation surrounding upcoming government and defense contract announcements. The community is actively debating the stock's potential for a short squeeze, citing high short interest and institutional accumulation, while some investors remain cautious about the company's path to consistent profitability.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is drawing significant investor attention as momentum builds around its enterprise cloud and AI infrastructure expansion, with traders closely watching for a potential breakout ahead of earnings. The community is actively debating the stock's role in the AI data center narrative, with many highlighting its massive revenue backlog as a key catalyst for long-term institutional accumulation.

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is trending following a standing ovation at ASCO for daraxonrasib's breakthrough survival data in metastatic pancreatic cancer. The community is actively discussing the drug's potential as a new standard of care, with heightened speculation regarding a significant valuation increase or potential acquisition by major pharmaceutical players.

Taylor Morrison Home Corp. engages in the business of residential homebuilding and the development of lifestyle communities. It operates through the following segments: East, Central, West, and Financial Services. The East segment includes operations in Atlanta, Charlotte, Chicago, Orlando, Raleigh, Southwest Florida, and Tampa regions. The Central segment consists of Austin, Dallas, Denver, Houston, and Indianapolis. The West segment covers Bay Area, Las Vegas, Phoenix, Portland, Sacramento, Seattle, and Southern California. The Financial Services segment refers to Taylor Morrison Home Funding, Inspired Title Services, and Taylor Morrison Insurance Services. The company was founded in 1936 and is headquartered in Scottsdale, AZ.

Taylor Morrison Home Corp.

Taylor Morrison Home Corp. is in the spotlight following an $8.5 billion all-cash acquisition agreement by Berkshire Hathaway, fueling community debate over the outlook for the housing sector and the potential for a broad market reprice. Investors are actively discussing the implications of Warren Buffett's pivot back into large-scale homebuilding during a period of shifting demand and interest rate volatility.

Summit Therapeutics, Inc. is a biopharmaceutical company, that focuses on the discovery, development, and commercialization of patient, physician, caregiver, and societal-friendly medicinal therapies intended to improve quality of life, increase potential duration of life, and resolve serious unmet medical needs. The firm conducts clinical programs focusing on Clostridioides Difficile Infection (CDI). Its lead product, Ridinilazole, is an orally administered small molecule antibiotic that is in Phase III clinical trials for the treatment of CDI. The company was founded in 2003 and is headquartered in Miami, FL.

Summit Therapeutics Inc

Summit Therapeutics is trending as investors digest recent ASCO plenary data that demonstrated a statistically significant survival benefit for ivonescimab, fueling intense community debate over its potential to challenge the current standard-of-care immunotherapy. While bulls point to these historic trial results as a major validation of the drug's efficacy, the discussion remains polarized by skepticism regarding the trial's comparator and the path to global regulatory adoption.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

After Golden Cross, AbCellera Biologics Inc. (ABCL)'s Technical Outlook is Bright

Should investors be excited or worried when a stock's 50-day simple moving average crosses above the 200-day simple moving average?

Wall Street Analysts Believe ABCELLERA BIOLG (ABCL) Could Rally 97.28%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 97.3% in ABCELLERA BIOLG (ABCL). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Are Medical Stocks Lagging  ABCELLERA BIOLG (ABCL) This Year?

Here is how AbCellera Biologics Inc. (ABCL) and Adlai Nortye Ltd. Sponsored ADR (ANL) have performed compared to their sector so far this year.

AbCellera Biologics Inc. (ABCL) Reports Q1 Loss, Beats Revenue Estimates

ABCELLERA BIOLG (ABCL) delivered earnings and revenue surprises of +36.36% and +68.12%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

AbCellera Reports Q1 2026 Business Results & Announces Positive Interim Phase 1 Clinical Data for ABCL635

AbCellera (Nasdaq: ABCL) today announced financial results for the first quarter of 2026 and positive interim results from the Phase 1 portion of its ongoing Phase 1/2 clinical trial of ABCL635...

ABCL Stock Clocks Best Week Since February On Clinical Data Anticipation, Baker Bros Stake Boost 

Equity

On Monday, AbCellera will release its financial results alongside interim early-stage data for its lead internal candidate ABCL635.


Absci Corporation (ABSI) Reports Q1 Loss, Misses Revenue Estimates

ABSCI CORP (ABSI) delivered earnings and revenue surprises of +5.00% and -90.00%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

AbCellera to Present at Upcoming Investor Conferences in May and June 2026

AbCellera (Nasdaq: ABCL) today announced that the Company will present at the following investor conferences: Bank of America Health Care Conference, May 13, 2026 Jefferies Global Healthcare Conference in New York, June 4, 2026 A live audio webcast of each presentation may be accessed through a...

Arcus Biosciences, Inc. (RCUS) Reports Q1 Loss, Beats Revenue Estimates

Arcus Biosciences (RCUS) delivered earnings and revenue surprises of -10.87% and +21.43%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?

AbCellera Biologics (NASDAQ:ABCL) Shares Gap Up   - What's Next?

AbCellera Biologics (NASDAQ:ABCL) Shares Gap Up - Here's Why...

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

Fiscal Period	Estimated	Reported	Surprise	Result
Q2 '26	-$0.14	--	--	N/A
Q1 '26	-$0.17	-$0.14	18.33%	BEAT
Q4 '25	-$0.13	-$0.03	77.61%	BEAT
Q3 '25	-$0.14	-$0.19	-36.94%	MISSED
Q2 '25	-$0.13	-$0.12	10.56%	BEAT

ABCL
AbCellera Biologics Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest Earnings Results: Q1 '26

Historical Earnings

Compact View

Latest ABCL News

ABCLAbCellera Biologics Inc